SCHEMBL1403565

SCHEMBL1403565

COc1ccc2cc(CCC(=O)O)ccc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.77
KDM4E B2RXH2 2/20 0.77
LMNA P02545 2/20 0.77
NPC1 O15118 1/20 0.77
TP53 P04637 1/20 0.77
CYP3A4 P08684 1/20 0.77
MAPT P10636 1/20 0.77
MAOA P21397 1/20 0.77
SLC6A2 P23975 1/20 0.77
RAB9A P51151 1/20 0.77
SLC6A3 Q01959 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
PTGS1 P23219 1/20 0.71
AKR1C3 P42330 1/20 0.71
AKR1C2 P52895 1/20 0.71
FFAR1 O14842 5/20 0.60
ALDH1A1 P00352 1/20 0.60
HPGD P15428 1/20 0.60
CYP2C19 P33261 1/20 0.60
HSD17B10 Q99714 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15802556 0.90 CYP1A2 (0.68) CYP1A2KDM4ELMNANPC1TP53
SCHEMBL3692541 0.88 CYP1A2 (0.68) CYP1A2KDM4ELMNANPC1TP53
Nabumetone SCHEMBL2256 0.87 CYP1A2 (1.00) CYP1A2KDM4ELMNANPC1TP53
SCHEMBL27706724 0.87 CYP1A2 (0.77) CYP1A2KDM4ELMNANPC1TP53
Nabumetone SCHEMBL29570823 0.87 CYP1A2 (1.00) CYP1A2KDM4ELMNANPC1TP53
Nabumetone SCHEMBL3853067 0.87 CYP1A2 (1.00) CYP1A2KDM4ELMNANPC1TP53
Nabumetone SCHEMBL29373228 0.87 CYP1A2 (1.00) CYP1A2KDM4ELMNANPC1TP53
SCHEMBL9670503 0.86 CYP1A2 (0.67) CYP1A2KDM4ELMNANPC1TP53
SCHEMBL4712374 0.85 CYP1A2 (0.74) CYP1A2KDM4ELMNANPC1TP53
Nabumetone SCHEMBL104942 0.85 CYP1A2 (0.97) CYP1A2KDM4ELMNANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071181-B2 Metal nanoparticle and use thereof for inducing chirality in liquid crystal phases UNIVERSITY OF MANITOBA (CA) 2011-12-06 US claimed
US-20090027611-A1 Metal Nanoparticle and Use Thereof for Inducing Chirality in Liquid Crystal Phases THE UNIVERSITY OF MANITOBA (CA) 2009-01-29 US claimed
US-20020183520-A1 Process to prepare (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2(1H)-one WUTS PETER GUILLAUME MARIE (US) 2002-12-05 US claimed
US-6355802-B1 Process to prepare (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2(1h)-one PHARMACIA & UPJOHN COMPANY 2002-03-12 US claimed
EP-1149100-A1 PROCESS TO PREPARE (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO 4,5,1-ij]-QUINOLIN-2(1H)-ONE PHARMACIA & UPJOHN COMPANY (US) 2001-10-31 EP claimed
WO-2000046226-A1 PROCESS TO PREPARE (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO[4,5,1-ij]-QUINOLIN-2(1H)-ONE PHARMACIA & UPJOHN COMPANY (US) 2000-08-10 WO claimed
US-4857462-A Process for obtaining D(+)-naproxen BOEHRINGER MANNHEIM GMBH (DE) 1989-08-15 US claimed
US-4723033-A REACTING ALPHA METAL ACID DERIVATIVE AND ARYL HALIDE WITH OPTICALLY ACTIVE CATALYST SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) 1988-02-02 US claimed
WO-2023171757-A1 POLYMER COMPOSITION, SINGLE LAYER PHASE DIFFERENCE MATERIAL, AND LIQUID CRYSTAL ALIGNMENT AGENT 日産化学株式会社 2023-09-14 WO disclosed
US-10788713-B2 Patterned liquid crystal alignment using ink-jet printed nanoparticles and use thereof to produce patterned, electro-optically addressable devices; ink-jet printable compositions KENT STATE UNIVERSITY (US) 2020-09-29 US disclosed
US-10545383-B2 Patterned liquid crystal alignment using ink-jet printed nanoparticles and use thereof to produce patterned, electro-optically addressable devices; ink-jet printable compositions KENT STATE UNIVERSITY (US) 2020-01-28 US disclosed
US-20190084943-A1 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY PARION SCIENCES, INC. (US) 2019-03-21 US disclosed
US-20190085245-A1 Patterned Liquid Crystal Alignment Using Ink-Jet Printed Nanoparticles and Use Thereof to Produce Patterned, Electro-Optically Addressable Devices; Ink-Jet Printable Compositions KENT STATE UNIVERSITY 2019-03-21 US disclosed
US-20190085244-A1 Patterned Liquid Crystal Alignment Using Ink-Jet Printed Nanoparticles and Use Thereof to Produce Patterned, Electro-Optically Addressable Devices; Ink-Jet Printable Compositions KENT STATE UNIVERSITY (US) 2019-03-21 US disclosed
US-4605758-A Preparation of α-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) 1986-08-12 US disclosed
EP-0178580-A2 Intermediates for the synthesis of carboxylic acids ZAMBON S.p.A. (IT) 1986-04-23 EP disclosed
EP-0163338-A1 Process for preparing naproxen Nobel Chemicals AB (SE) 1985-12-04 EP disclosed
EP-0022529-B1 PROCESS FOR THE RESOLUTION OF D,L 2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID; A MIXTURE OF THE SALTS OF THESE D AND L ACIDS; A PHARMACEUTICAL COMPOSITION CONTAINING A SALT OF THE D ACID; A SALT OF THE D ACID SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1983-06-29 EP disclosed
EP-0081993-A2 Optically active alpha-substituted aryl ketones, their preparation and their use in preparing alpha-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1983-06-22 EP disclosed
US-3936528-A 2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID OR SALT AND CODEINE OR PROPOXYPHENE SYNTEX CORPORATION (US) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090027611-A1 Metal Nanoparticle and Use Thereof for Inducing Chirality in Liquid Crystal Phases NCL, AUP1, PIN1 CYP1A2 3130/4885KDM4E 3963/4885LMNA 3358/4885
US-20020183520-A1 Process to prepare (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2(1H)-one CYP2S1, HTR3C, HTR3A CYP1A2 21/4885KDM4E 304/4885LMNA 400/4885
US-20190084943-A1 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY SCNN1B, SCNN1A, SCNN1G CYP1A2 1710/4885KDM4E 2881/4885LMNA 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.